Drug Retail

SIPAI HEALTH

SIPAI HEALTH released FY2025 Q3 earnings on March 30, 2026 (BJT), with actual revenue of HKD 462.91 M and EPS of HKD -0.0483

SIPAI HEALTH released FY2025 9 Months Earnings on March 30 (BJT), actual revenue HKD 1.788 B, actual EPS HKD -0.1754

SIPAI HEALTH released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue HKD 470.9 M, actual EPS HKD -0.0509

SIPAI HEALTH released FY2025 Annual Earnings on March 30 After-Market (BJT), actual revenue HKD 2.264 B (forecast HKD 5.38 B), actual EPS HKD -0.2255

SIPAI HEALTH to release FY2025 earnings on March 30 After-Market BJT, forecast revenue HKD 5.38 B

CSpider Health Technology repurchased 1.656 million shares

Cancer Pine Health Technology repurchased 2,526,600 shares

Ciberhealth Technology Sees Narrowed Losses in H1 2025 and Undertakes Strategic Adjustments

SIPAI HEALTH released FY2025 Q1 earnings on August 18 (BJT), actual revenue HKD 655.47 M, actual EPS HKD -0.0642

SIPAI HEALTH released FY2025 Q2 earnings on August 18 After-Market (BJT), actual revenue HKD 669.88 M, actual EPS HKD -0.0642

SIPAI HEALTH released FY2025 Semi-Annual earnings on August 18 After-Market (BJT), actual revenue HKD 1.325 B, actual EPS HKD -0.1271

SIPAI HEALTH to Release FY2025 Semi-Annual Earnings on August 18, 2025 (BJT)

CancerPing Health Soars Over 13% on New Medical Insurance Policy

CancerAid's Stock Soars with Health Bureau Policy Support and Investment Boost

CancerPI Health Shares Surge, Partners with Evercare

Caresketch Health spent HKD 97,900 to repurchase 20,000 shares

Crown Health Subscribes to $30 Million Citibank Financial Product

Cancer-patient Service Provider Cura Healthcare Redeems HSBC's $23.7 Million Wealth Management Product

CancerPing Health Partners with AmTrust to Develop Customized Insurance Solutions

Crob Medical Repurchased 20,000 Shares

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

TOP EDUCATION

ZXZN QI-HOUSE

C&N HOLDINGS

DIGIT HOLLYWOOD

XL2CSOPHYNIX

MOON INC

HUISHENG INTL

00314

Sipai Health Technology Co., Ltd. has agreed to divest 100% of a wholly owned subsidiary and two additional subsidiaries to Dashenlin for RMB51.73 million. This transaction, which is subject to consideration adjustments, will streamline Sipai's operations and financial reporting. The deal is classified as a discloseable transaction under Hong Kong Listing Rules, requiring notification but not a shareholder vote. Sipai will provide further details in a subsequent announcement, noting that the transaction is conditional and may not proceed.

Tip Ranks

Sipai Health Technology to Divest Subsidiary Group to Dashenlin for RMB51.73 Million

SIPAI HEALTH announced its 2025 annual performance, with revenue recorded at RMB 2.071 billion, a year-on-year decrease of 54.6%. The loss narrowed from RMB 324 million in the previous year to RMB 124 million, with a loss per share of 21 cents. No final dividend will be distributed

AASTOCKS

"SIPAI HEALTH" narrowed its annual loss to 124 million RMB

As of the close on March 5th, SIPAI HEALTH is approaching recent support levels, with limited strength in intraday rebounds and ongoing pressure. Trading volume is neutral to low, with funds opting to wait for clearer catalysts. Over the past week, discussions have taken place in multiple regions regarding the integration of commercial insurance and internet healthcare, with details on payment standards becoming a focal topic. The market interprets this as "signs of marginal policy easing, but implementation and profit transmission will take time," leading to a cautious approach to expanding risk exposure. The stock price still lacks continuous upward momentum, with daily momentum being weak. 

From a market linkage perspective, the simultaneous rise and fall of medical informatization and insurtech stocks has become more frequent, indicating that sector funds are searching for certainty through trial and error. If there are clear collaborations or clarified charging models, these are typically seen as triggers for emotional recovery; for example: a marginal increase in willingness to pay from medical insurance or commercial insurance, expansion of platform collaborations, and improvements in service pricing and penetration rates could all serve as catalysts. Currently, the market is still in a "news expectation period," with funds remaining sensitive to changes in realization paths and standards.

Technically, short-term moving averages are exerting pressure on prices, and MACD is weakly oscillating below the zero axis; if the stock price can recover key areas with increased volume and stabilize on subsequent pullbacks with reduced volume, while showing a stepwise increase in intraday lows, the probability of trend continuation will significantly increase. Conversely, if trading volume cannot effectively expand or if pullbacks break support, the bottom oscillation pattern may persist. 

Risk warnings include the possibility of policy details being inconsistent, commercialization progressing slower than expected, and false rebounds triggered by market liquidity contraction; if macro risk appetite declines or regulatory standards tighten, valuation recovery will be hindered

Technical Forecast

Morning Trend | SIPAI HEALTH (0314.HK) Approaching Support, Is a Rebound Coming Under the Policy Window?

SIPAI HEALTH(00314.HK)

Sipai Health Technology to Divest Subsidiary Group to Dashenlin for RMB51.73 Million

"SIPAI HEALTH" narrowed its annual loss to 124 million RMB

Morning Trend | SIPAI HEALTH (0314.HK) Approaching Support, Is a Rebound Coming Under the Policy Window?